A Panoply of Rheumatological Manifestations in Patients with GATA2 Deficiency.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
20 05 2020
20 05 2020
Historique:
received:
31
01
2020
accepted:
23
04
2020
entrez:
21
5
2020
pubmed:
21
5
2020
medline:
15
12
2020
Statut:
epublish
Résumé
To characterize rheumatological manifestations of GATA2 deficiency. Single-center, retrospective review of 157 patients with GATA2 deficiency. Disease course, laboratory results, and imaging findings were extracted. In-person rheumatological assessments were performed on selected, available patients. A literature search of four databases was conducted to identify additional cases. Rheumatological findings were identified in 28 patients, out of 157 cases reviewed (17.8%). Twenty-two of those patients (78.6%) reported symptom onset prior to or in conjunction with the molecular diagnosis of GATA2 deficiency. Notable rheumatological manifestations included: piezogenic pedal papules (PPP), joint hyperextensibility, early onset osteoarthritis, ankylosing spondylitis, and seronegative erosive rheumatoid arthritis. In peripheral blood of patients with rheumatological manifestations and GATA2 deficiency, CD4+ CD3+ helper T cells and naïve CD3+ CD4+ CD62L+ CD45RA+ helper T cell subpopulation fractions were significantly lower, while CD8+ cytotoxic T cell fractions were significantly higher, compared to those without rheumatological manifestations and with GATA2 deficiency. No changes in CD19, CD3, or NK populations were observed. GATA2 deficiency is associated with a broad spectrum of rheumatological disease manifestations. Low total helper T lymphocyte proportions and low naïve helper T cell proportions are associated with those most at risk of overt rheumatological manifestations. Further, PPP and joint hyperextensibility may explain some of the nonimmunologically-mediated joint problems encountered in patients with GATA2 deficiency. This catalogue suggests that rheumatological manifestations and immune dysregulation are relatively common in GATA2 deficiency.
Identifiants
pubmed: 32433473
doi: 10.1038/s41598-020-64852-1
pii: 10.1038/s41598-020-64852-1
pmc: PMC7239896
doi:
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
8305Références
Spinner, M. A. et al. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood 123, 809–821 (2014).
doi: 10.1182/blood-2013-07-515528
Donadieu, J. et al. Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients. haematologica 103, 1278–1287 (2018).
doi: 10.3324/haematol.2017.181909
Mace, E. M. & Orange, J. S. Emerging insights into human health and NK cell biology from the study of NK cell deficiencies. Immunological reviews 287, 202–225 (2019).
doi: 10.1111/imr.12725
Cuellar-Rodriguez, J. et al. Successful allogeneic hematopoietic stem cell transplantation for GATA2 deficiency. Blood 118, 3715–3720, https://doi.org/10.1182/blood-2011-06-365049 (2011).
doi: 10.1182/blood-2011-06-365049
pubmed: 21816832
pmcid: 3186343
Johnson, J. A., Yu, S. S., Elist, M., Arkfeld, D. & Panush, R. S. Rheumatologic manifestations of the “MonoMAC” syndrome. a systematic review. Clinical Rheumatology 34, 1643–1645, https://doi.org/10.1007/s10067-015-2905-2 (2015).
doi: 10.1007/s10067-015-2905-2
pubmed: 25739845
Vinh, D. C. et al. Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. Blood 115, 1519–1529 (2010).
doi: 10.1182/blood-2009-03-208629
Bigley, V. & Matthew, C. Dendritic cell, monocyte, B and NK lymphoid deficiency defines the lost lineages of a new GATA-2 dependent myelodysplastic syndrome. Haematologica, 1081–1083 (2011).
Bigley, V. et al. The human syndrome of dendritic cell, monocyte, B and NK lymphoid deficiency. Journal of Experimental Medicine 208, 227–234 (2011).
doi: 10.1084/jem.20101459
Ishida, H. et al. GATA-2 anomaly and clinical phenotype of a sporadic case of lymphedema, dendritic cell, monocyte, B- and NK-cell (DCML) deficiency, and myelodysplasia. European Journal of Pediatrics 171, 1273–1276, https://doi.org/10.1007/s00431-012-1715-7 (2012).
doi: 10.1007/s00431-012-1715-7
pubmed: 22430350
Camargo, J. F. et al. MonoMAC syndrome in a patient with a GATA2 mutation: Case report and review of the literature. Clinical Infectious Diseases 57, 697–699, https://doi.org/10.1093/cid/cit368 (2013).
doi: 10.1093/cid/cit368
pubmed: 23728141
pmcid: 3739466
Prader, S. et al. Life-threatening primary varicella zoster virus infection with hemophagocytic lymphohistiocytosis-like disease in GATA2 haploinsufficiency accompanied by expansion of double negative T-lymphocytes. Frontiers in immunology 9, 2766 (2018).
doi: 10.3389/fimmu.2018.02766
Polat, A. et al. Skin manifestations among GATA2-deficient patients. British Journal of Dermatology 178, 781–785, https://doi.org/10.1111/bjd.15548 (2018).
doi: 10.1111/bjd.15548
pubmed: 28440875
Damian, L. et al. Pseudo-Sarcoidosis Revealing MonoMAC Syndrome. Journal of Clinical Immunology 38, 739–741, https://doi.org/10.1007/s10875-018-0551-6 (2018).
doi: 10.1007/s10875-018-0551-6
pubmed: 30280306
Dickinson, R. E. et al. The evolution of cellular deficiency in GATA2 mutation. Blood 123, 863–874 (2014).
doi: 10.1182/blood-2013-07-517151
Ringold, S. et al. American College of Rheumatology/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non‐systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis care & research 71, 717–734 (2019).
doi: 10.1002/acr.23870
Silva, B. C. & Leslie, W. D. Trabecular bone score: a new DXA–derived measurement for fracture risk assessment. Endocrinology and Metabolism Clinics 46, 153–180 (2017).
doi: 10.1016/j.ecl.2016.09.005
Han, X., Boyd, P. J., Colgan, S., Madri, J. A. & Haas, T. L. Transcriptional up-regulation of endothelial cell matrix metalloproteinase-2 in response to extracellular cues involves GATA-2. Journal of Biological Chemistry 278, 47785–47791 (2003).
doi: 10.1074/jbc.M309482200
Rastogi, A., Kim, H., Twomey, J. D. & Hsieh, A. H. MMP-2 mediates local degradation and remodeling of collagen by annulus fibrosus cells of the intervertebral disc. Arthritis research & therapy 15, R57 (2013).
doi: 10.1186/ar4224
Tolkachov, A. et al. Loss of the Hematopoietic Stem Cell Factor GATA2 in the Osteogenic Lineage Impairs Trabecularization and Mechanical Strength of Bone. Mol Cell Biol 38, https://doi.org/10.1128/mcb.00599-17 (2018).
Wei, W. et al. Osteoclast progenitors reside in the peroxisome proliferator-activated receptor gamma-expressing bone marrow cell population. Mol Cell Biol 31, 4692–4705, https://doi.org/10.1128/mcb.05979-11 (2011).
doi: 10.1128/mcb.05979-11
pubmed: 21947280
pmcid: 3232921
Wei, W. et al. Biphasic and dosage-dependent regulation of osteoclastogenesis by beta-catenin. Mol Cell Biol 31, 4706–4719, https://doi.org/10.1128/mcb.05980-11 (2011).
doi: 10.1128/mcb.05980-11
pubmed: 21876000
pmcid: 3232928
Moos, S., Mohebiany, A. N., Waisman, A. & Kurschus, F. C. Imiquimod-Induced Psoriasis in Mice Depends on the IL-17 Signaling of Keratinocytes. Journal of Investigative Dermatology 139, 1110–1117 (2019).
doi: 10.1016/j.jid.2019.01.006
Machler, B., Mark, N., Patel, U. & Levine, V. Imiquimod induced psoriasis: A case report, review of the literature, and pathophysiologic mechanism: P3313. Journal of the American Academy of Dermatology 64 (2011).
Bugault, F. et al. Altered responses to homeostatic cytokines in patients with idiopathic CD4 lymphocytopenia. PloS one 8, e55570 (2013).
doi: 10.1371/journal.pone.0055570
Wehr, C. et al. A new CD21low B cell population in the peripheral blood of patients with SLE. Clinical immunology 113, 161–171 (2004).
doi: 10.1016/j.clim.2004.05.010
Thorarinsdottir, K. et al. CD 21‐/low B cells associate with joint damage in rheumatoid arthritis patients. Scandinavian journal of immunology, e12792 (2019).
Saadoun, D. et al. Expansion of autoreactive unresponsive CD21−/low B cells in Sjögren’s syndrome–associated lymphoproliferation. Arthritis & Rheumatism 65, 1085–1096 (2013).
doi: 10.1002/art.37828
Illges, H., Braun, M., Peter, H. & Melchers, I. Reduced expression of the complement receptor type 2 (CR2, CD21) by synovial fluid B and T lymphocytes. Clinical & Experimental Immunology 122, 270–276 (2000).
doi: 10.1046/j.1365-2249.2000.01379.x
Yeo, L. et al. Expression of FcRL4 defines a pro-inflammatory, RANKL-producing B cell subset in rheumatoid arthritis. Annals of the rheumatic diseases 74, 928–935 (2015).
doi: 10.1136/annrheumdis-2013-204116
Mensah, K. A. et al. Impaired ATM activation in B cells is associated with bone resorption in rheumatoid arthritis. Science Translational Medicine 11 (2019).
Grant, C. R., Liberal, R., Mieli-Vergani, G., Vergani, D. & Longhi, M. S. Regulatory T-cells in autoimmune diseases: challenges, controversies and—yet—unanswered questions. Autoimmunity reviews 14, 105–116 (2015).
doi: 10.1016/j.autrev.2014.10.012